期刊
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
卷 28, 期 6, 页码 919-925出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/ijmm.2011.768
关键词
liver fibrosis; hepatic stellate cell; transforming growth factor-beta; valproate
资金
- Grants-in-Aid for Scientific Research [23591981, 22249051, 22591515] Funding Source: KAKEN
Histone acetylation and deacetylation have been thought to be related to gene expression, and there are many reports indicating that histone deacetylase inhibitors (HDACis) exert antifibrogenic effects in several organs. In injured livers, hepatic stellate cells (HSCs) are activated in response to profibrogenic mediators and produce large amounts of extracellular matrix. In particular, transforming growth factor-beta 1 (TGF-beta 1) is considered as a key factor in accelerating hepatic fibrosis because it is released from activated HSCs and further stimulates them. The present study aimed to clarify whether sodium valproate (VPA) has suppressive effects on cultured human HSCs (LI90). We showed that treatment with VPA had no significantly suppressive effect on cell proliferation at a concentration of 1 mM, which corresponded approximately to the serum concentration obtained by the administration of a clinical dose. However, VPA prevented the morphological changes characteristic for activation and inhibited the expression of collagen type 1 alpha 1 (COLIAI) and TGF-beta 1 in activated LI90 cells at the mRNA and protein levels. Our results support the hypothesis that VPA exerts antifibrogenic activity with little cytotoxicity at 1 mM, and HDACis are expected to be used in clinical practice for the treatment of fibrotic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据